BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 36907877)

  • 1. An EMT-based gene signature enhances the clinical understanding and prognostic prediction of patients with ovarian cancers.
    Li QJ; Wu ZL; Wang J; Jiang J; Lin B
    J Ovarian Res; 2023 Mar; 16(1):51. PubMed ID: 36907877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction and validation of a novel aging-related gene signature and prognostic nomogram for predicting the overall survival in ovarian cancer.
    Liu L; Zhao J; Du X; Zhao Y; Zou C; Zhou H; Li W; Yan X
    Cancer Med; 2021 Dec; 10(24):9097-9114. PubMed ID: 34825509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel immune-related gene signature for risk stratification and prognosis prediction in ovarian cancer.
    Fei H; Han X; Wang Y; Li S
    J Ovarian Res; 2023 Oct; 16(1):205. PubMed ID: 37858138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of copper metabolism-related subtypes and establishment of the prognostic model in ovarian cancer.
    Zhao S; Zhang X; Gao F; Chi H; Zhang J; Xia Z; Cheng C; Liu J
    Front Endocrinol (Lausanne); 2023; 14():1145797. PubMed ID: 36950684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4+ conventional T cells-related genes signature is a prognostic indicator for ovarian cancer.
    Hua T; Liu DX; Zhang XC; Li ST; Yan P; Zhao Q; Chen SB
    Front Immunol; 2023; 14():1151109. PubMed ID: 37063862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenic cell death-related gene landscape predicts the overall survival and immune infiltration status of ovarian cancer.
    Zhang W; Liu T; Jiang L; Chen J; Li Q; Wang J
    Front Genet; 2022; 13():1001239. PubMed ID: 36425071
    [No Abstract]   [Full Text] [Related]  

  • 7. Construction and validation of a transcription factors-based prognostic signature for ovarian cancer.
    Cheng Q; Li L; Yu M
    J Ovarian Res; 2022 Feb; 15(1):29. PubMed ID: 35227285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomics and prognosis analysis of epithelial-mesenchymal transition in colorectal cancer patients.
    Zhang Z; Zheng S; Lin Y; Sun J; Ding N; Chen J; Zhong J; Shi L; Xue M
    BMC Cancer; 2020 Nov; 20(1):1135. PubMed ID: 33228590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Machine learning-assisted analysis of epithelial mesenchymal transition pathway for prognostic stratification and immune infiltration assessment in ovarian cancer.
    Li Q; Xiao X; Feng J; Yan R; Xi J
    Front Endocrinol (Lausanne); 2023; 14():1196094. PubMed ID: 37404304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and validation of a seven m6A-related lncRNAs signature predicting prognosis of ovarian cancer.
    Song Y; Qu H
    BMC Cancer; 2022 Jun; 22(1):633. PubMed ID: 35676619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of an Autophagy-Related Signature for Prognosis and Immunotherapy Response Prediction in Ovarian Cancer.
    Ding J; Wang C; Sun Y; Guo J; Liu S; Cheng Z
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishing a Prognostic Signature Based on Epithelial-Mesenchymal Transition-Related Genes for Endometrial Cancer Patients.
    Liu J; Cui G; Shen S; Gao F; Zhu H; Xu Y
    Front Immunol; 2021; 12():805883. PubMed ID: 35095892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A signature based on glycosyltransferase genes provides a promising tool for the prediction of prognosis and immunotherapy responsiveness in ovarian cancer.
    Xu X; Wu Y; Jia G; Zhu Q; Li D; Xie K
    J Ovarian Res; 2023 Jan; 16(1):5. PubMed ID: 36611197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of STEAP3-based molecular subtype and risk model in ovarian cancer.
    Zhao Z; Sun C; Hou J; Yu P; Wei Y; Bai R; Yang P
    J Ovarian Res; 2023 Jun; 16(1):126. PubMed ID: 37386521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic prediction and immune infiltration analysis based on ferroptosis and EMT state in hepatocellular carcinoma.
    Liu Z; Wang J; Li S; Li L; Li L; Li D; Guo H; Gao D; Liu S; Ruan C; Dang X
    Front Immunol; 2022; 13():1076045. PubMed ID: 36591279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Epithelial-Mesenchymal Transition- (EMT-) Related LncRNA for Prognostic Prediction and Risk Stratification in Esophageal Squamous Cell Carcinoma.
    Wang P; Chen Y; Zheng Y; Fu Y; Ding Z
    Dis Markers; 2021; 2021():5340240. PubMed ID: 34712369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An EMT-Related Gene Signature to Predict the Prognosis of Triple-Negative Breast Cancer.
    Zhang B; Zhao R; Wang Q; Zhang YJ; Yang L; Yuan ZJ; Yang J; Wang QJ; Yao L
    Adv Ther; 2023 Oct; 40(10):4339-4357. PubMed ID: 37462865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of an ovarian cancer omentum metastasis-related prognostic model by integrated analysis of scRNA-seq and bulk RNA-seq.
    Zhang D; Lu W; Cui S; Mei H; Wu X; Zhuo Z
    J Ovarian Res; 2022 Nov; 15(1):123. PubMed ID: 36424614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
    Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
    Front Immunol; 2022; 13():943389. PubMed ID: 36003381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.
    Li H; Lin D; Yu Z; Li H; Zhao S; Hainisayimu T; Liu L; Wang K
    Front Immunol; 2022; 13():947802. PubMed ID: 36405735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.